Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease
Open Access
- 24 May 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (6)
Abstract
Intestinal fibrosis in inflammatory bowel disease (IBD) is caused by uncontrolled accumulation of extracellular matrix deposited by fibroblasts. This may result in stricture formation, especially in Crohn’s disease. Since there are no anti-fibrotic drugs available, endoscopic or surgical interventions are the only options to treat intestinal strictures. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway plays a crucial role in intestinal homeostasis and inflammation. JAK inhibition represents a relatively novel therapeutic strategy in IBD by simultaneously blocking multiple cytokines across various inflammatory pathways. Interestingly, JAK inhibitors extend their benefits beyond anti-inflammatory effects, as they have been shown to interfere with fibrotic processes in various diseases, including IBD. We here summarize the current understanding of the role of the JAK-STAT pathway in the pathogenesis of intestinal fibrosis and the application of JAK inhibitors for IBD. In addition, we discuss the use of JAK inhibitors in other fibrotic-related diseases to postulate how these agents might be applied for future treatment of intestinal fibrosis.Keywords
Funding Information
- ECCO Pioneer award
- NWO Veni
- FIBROTARGET (101080523)
- ECCO Pioneer Award.
- FWO-Research Foundation – Flanders (11PF324N)
- China Scholarship Council (202206170019)
This publication has 119 references indexed in Scilit:
- Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?European Respiratory Journal, 2007
- STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicityHepatology, 2006
- Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 productionOncogene, 2006
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- Cytokines, STATs and liver disease.2005
- Liver fibrosisJournal of Clinical Investigation, 2005
- The Janus kinases (Jaks)Genome Biology, 2004
- STATs: transcriptional control and biological impactNature Reviews Molecular Cell Biology, 2002
- The conversion of redox status of peritoneal macrophages during pathological progression of spontaneous inflammatory bowel disease in Janus family tyrosine kinase 3–/– and IL‐2 receptor γ–/– miceInternational Immunology, 2002
- Regulated nuclear import of the STAT1 transcription factor by direct binding of importin‐αThe EMBO Journal, 2002